Watch the video interview with John S. Ikonomidis, M.D., Chief of the Division of Cardiothoracic Surgery at MUSC, and Daniel H. Steinberg, M.D., an interventional cardiologist at the MUSC Heart and Vascular Center, discussing transcathether aortic-valve replacement (TAVR), a minimally invasive alternative to surgical aortic-valve replacement in select patients with severe aortic stenosis. TAVR is already approved for inoperable patients and has been recommended for approval by an FDA advisory panel in high-risk surgical patients. Drs. Ikonomidis and Steinberg also discuss MUSC's involvement as a site in the PARTNER 2 trial, which will examine the use of a smaller device in intermediate-risk surgical patients.
News & Events
Drs. Ikonomidis and Steinberg discuss how TAVR will change the care of patients with aortic stenosis
Posted by: Kimberly McGhee
Keywords: aortic stenosis, catheter, heart, heart failure, inoperable, medical university of south carolina, minimally invasive, partner 2, partner trial, severe aortic stenosis, south carolina heart valve center, tavi, tavr, transcatheter aortic-valve implantation, transcatheter aortic-valve replacement